Pfizer Inc (PFE)

PFE on New York Consolidated

35.01USD
20 Apr 2015
Change (% chg)

$-0.03 (-0.09%)
Prev Close
$35.04
Open
$35.04
Day's High
$35.24
Day's Low
$34.94
Volume
22,402,767
Avg. Vol
29,827,875
52-wk High
$35.53
52-wk Low
$27.51

PFE

Chart for PFE

About

Pfizer Inc. is a bio pharmaceutical company. The company applies science and resources to discover, develop and manufacture healthcare products. The Company provides medicines, vaccines and consumer healthcare products. The Company operates its business through three operating segments, which include Global Innovative Pharmaceut... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $215,157.30
Shares Outstanding(Mil.): 6,140.33
Dividend: 0.28
Yield (%): 3.20

Financials

  PFE Industry Sector
P/E (TTM): 24.72 40.59 41.17
EPS (TTM): 1.42 -- --
ROI: 6.17 16.74 16.08
ROE: 12.32 17.27 16.92
Search Stocks

Pfizer wins first U.S. trial over Zoloft birth-defect risk

- Pfizer Inc scored a key victory Friday when it was cleared of liability in the first U.S. trial involving claims that its antidepressant Zoloft can cause birth defects in children born to women who take the drug while pregnant.

17 Apr 2015

Pfizer wins first U.S. trial over Zoloft birth-defect risk

- Pfizer Inc scored a key victory Friday when it was cleared of liability in the first U.S. trial involving claims that its antidepressant Zoloft can cause birth defects in children born to women who take the drug while pregnant.

17 Apr 2015

UPDATE 2-Pfizer wins first U.S. trial over Zoloft birth-defect risk

April 17 - Pfizer Inc scored a key victory Friday when it was cleared of liability in the first U.S. trial involving claims that its antidepressant Zoloft can cause birth defects in children born to women who take the drug while pregnant.

17 Apr 2015

Bristol's Opdivo proves effective against second type of lung cancer

- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.

17 Apr 2015

UPDATE 2-Bristol's Opdivo proves effective against second type of lung cancer

April 17 - A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.

17 Apr 2015

Approved Pfizer breast cancer drug impresses in latest study

- Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.

15 Apr 2015

Approved Pfizer breast cancer drug impresses in latest study

April 15 - Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.

15 Apr 2015

AstraZeneca science is on the move, one year on from Pfizer bid

LONDON - Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move -- quite literally.

15 Apr 2015

AstraZeneca science is on the move, one year on from Pfizer bid

* New drugs make progress, high hopes in lung cancer treatment

15 Apr 2015

Pfizer spars with Zoloft plaintiffs over deadline for new expert

- Pfizer Inc has asked a federal judge in Pennsylvania to reject plaintiffs' request for more time to find a new expert who can testify that its antidepressant Zoloft can cause birth defects in children born to women who took the drug while pregnant.

14 Apr 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $100.21 +0.63
Novartis AG (NOVN.VX) CHF97.70 +0.50
Merck & Co., Inc. (MRK.N) $57.61 +0.73
Roche Holding Ltd. (ROG.VX) CHF273.10 +2.90
Abbott Laboratories (ABT.N) $46.63 +0.38
Bayer AG (BAYGn.DE) €136.80 +3.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €96.16 +0.51
AstraZeneca plc (AZN.L) 4,803.00p +53.00
GlaxoSmithKline plc (GSK.L) 1,581.00p +5.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks